These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36394714)

  • 21. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
    Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
    Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Jack D; Vermersch P
    Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
    Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; Verdun di Cantogno E
    Mult Scler; 2023 May; 29(6):719-730. PubMed ID: 37012898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
    Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; di Cantogno EV
    Neurodegener Dis Manag; 2023 Oct; 13(5):261-268. PubMed ID: 37535336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B; Guerreiro R; Costa J; Miguel LS
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates.
    Inshasi JS; Alfahad S; Alsaadi T; Hassan A; Zein T; Mifsud VA; Nouri SI; Shakra M; Shatila AO; Szolics M; Thakre M; Kumar A; Boshra A
    Neurol Ther; 2021 Dec; 10(2):435-454. PubMed ID: 33891277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
    Meuth SG; Bayas A; Kallmann B; Kleinschnitz C; Linker R; Rieckmann P; Mäurer M
    Expert Opin Pharmacother; 2020 Nov; 21(16):1965-1969. PubMed ID: 32658554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
    Rammohan K; Coyle PK; Sylvester E; Galazka A; Dangond F; Grosso M; Leist TP
    Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
    Giovannoni G; Singer BA; Issard D; Jack D; Vermersch P
    Mult Scler; 2022 Jul; 28(8):1219-1228. PubMed ID: 34634968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment continuation with cladribine at 5 years after initiation in people with multiple sclerosis: A case series and literature review.
    Arun T; Shehu A; Pye E; Smith L; Meehan M
    Mult Scler Relat Disord; 2024 Oct; 90():105837. PubMed ID: 39180839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
    Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
    Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
    Negrotto L; Iut VC; Etchepare A; D'Eramo M; Grinspan A; Assefi A
    Mult Scler Relat Disord; 2022 Dec; 68():104403. PubMed ID: 36544327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals.
    Shephard A; Kolaczkowski L; Barker N; Nahal D; Oreja-Guevara C; Reyes S; Gray H; Salloukh H; Giovannoni G
    Neurol Ther; 2024 Aug; 13(4):1015-1038. PubMed ID: 38760637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study.
    Rammohan K; Giovannoni G; Comi G; Cook S; Rieckmann P; Soelberg Sørensen P; Vermersch P; Hamlett A; Kurukulasuriya N;
    Mult Scler Relat Disord; 2012 Jan; 1(1):49-54. PubMed ID: 25876451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets - expert opinion on issues in clinical practice.
    Stangel M; Becker V; Elias-Hamp B; Havla J; Grothe C; Pul R; Rau D; Richter S; Schmidt S
    Mult Scler Relat Disord; 2021 Sep; 54():103075. PubMed ID: 34261026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
    Leist T; Cook S; Comi G; Montalban X; Giovannoni G; Nolting A; Damian D; Syed S; Galazka A
    Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
    Alroughani R; Al-Hashel J; Ahmed SF
    Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence.
    Oreja-Guevara C; Brownlee W; Celius EG; Centonze D; Giovannoni G; Hodgkinson S; Kleinschnitz C; Havrdova EK; Magyari M; Selchen D; Vermersch P; Wiendl H; Van Wijmeersch B; Salloukh H; Yamout B
    Mult Scler Relat Disord; 2023 Jan; 69():104459. PubMed ID: 36565573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.